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Introduction
The cell cycle is critical for maintaining genomic and chromosomal stability. An aberrant cell cycle results in the proliferation of cancer cells; indeed, it is a hallmark of human cancers. Therefore, targeting the cell cycle is a promising approach to inhibit cancer cell proliferation. Mitosis is one process that can be targeted, and several microtubuletargeting drugs such as taxol and vinca alkaloids are used for cancer treatment. However, because these drugs have side effects, other classes of anti-mitotic agent have been developed (Dominguez-Brauer et al., 2015) . Cellular mitosis involves the segregation of chromosomes into two daughter cells. This requires the bipolar attachment of spindles to sister chromatid kinetochores. The absence of attachment between the chromosomes and mitotic spindles results in the inactivation of anaphase-promoting complex/cyclosome (APC/C), and cells stop entering the anaphase until correct attachment to kinetochores is achieved. This delay in anaphase onset is called the spindle assembly checkpoint (SAC) or the mitotic checkpoint. SAC activation requires the assembly of the mitotic checkpoint complex (MCC), and a diverse set of proteins, including kinases and phosphatases (Musacchio, 2015) . Therefore, mitotic kinase inhibitors that target the SAC are potential anti-cancer drugs.
One of the critical mitotic kinases is monopolar spindle kinase 1 Mps1. Mps1 was identified in a budding yeast mutant that harbours a defect in the spindle pole body (yeast centrosome) duplication process, resulting in a monopolar spindle (Winey et al., 1991) . Mps1 phosphorylates serine, threonine and tyrosine in vitro; thus, it is a dual specificity protein kinase TTK (Lauze et al., 1995) . Intermolecular autophosphorylation of Mps1 within its activation loop increases its kinase activity (Mattison et al., 2007; Sun et al., 2010) . Mps1 is localized within centrosomes and kinetochores and associates with microtubules (Dou et al., 2003; Liu et al., 2003; Stucke et al., 2004) . Orthologues of Mps1 are found in most eukaryotes. Human Mps1 controls various steps during mitosis including centrosome duplication, spindle assembly, bipolar spindle attachment, the mitotic checkpoint, mitotic exit and cytokinesis (Liu and Winey, 2012) . Substrate phosphorylation by Mps1 plays a role in mitotic functions. Mps1 phosphorylates borealin to control aurora kinase B activity (Jelluma et al., 2008) , Knl1 to recruit MCC components (Yamagishi et al., 2012) , Mad2 to maintain SAC-induced arrest (Zich et al., 2012) , Mad3/BubR1 to correct kinetochore attachment (Huang et al., 2008) , Dam1 to couple kinetochores to microtubules (Shimogawa et al., 2006) and Hec1/Ndc80 to activate the SAC (Kemmler et al., 2009) . Chemical or RNAi-based inhibition of Mps1 have confirmed its role in mitosis (Dou et al., 2015; Jemaa et al., 2016) . Therefore, suppression of Mps1 could be an anti-mitotic target.
Mps1 is overexpressed in several human cancer tissues or cells including breast, glioma, liver, lung, pancreas and thyroid (Yuan et al., 2006; Salvatore et al., 2007; Landi et al., 2008; Daniel et al., 2011; Maire et al., 2013; Tannous et al., 2013; Liang et al., 2014; Slee et al., 2014) . A high expression of Mps1 is associated with poor survival of patients with glioma and pancreatic cancer (Tannous et al., 2013; Slee et al., 2014; Maachani et al., 2015) , although it is associated with better survival in those with triple-negative breast cancer (Maire et al., 2013) . In addition, the Mps1-encoding TTK gene is highly mutated in colorectal cancer with microsatellite instability (Niittymaki et al., 2011) . Therefore, the overexpression or mutation of Mps1 is associated with tumourigenesis.
Several Mps1 inhibitors including AZ3146 (Hewitt et al., 2010) , BAY1161909 (Wengner et al., 2016) , BAY1217389 (Wengner et al., 2016) , CFI-402257 (Liu et al., 2016) , MPI-0479605 (Tardif et al., 2011) , Mps BAY1 (Jemaa et al., 2013) , Mps BAY2a (Jemaa et al., 2013) , Mps1-IN-1 (Kwiatkowski et al., 2010) , Mps1-IN-2 (Kwiatkowski et al., 2010 ), Mps1-IN-3 (Tannous et al., 2013 , NMS-P715 (Colombo et al., 2010) , NTRC 0060-0 (Maia et al., 2015) , reversine and SP600125 (Schmidt et al., 2005) have been developed, and some are undergoing clinical trials. Recently, a novel Mps1 inhibitor, TC Mps1 12, which has a diaminopyridine-based structure, was designed and shown to inhibit tumour growth in an A549 xenograft model (Kusakabe et al., 2012) . However, its mechanism of action has not been examined.
Human hepatocellular carcinoma (HCC) is the most common and aggressive type of liver cancer. However, conventional chemotherapy is limited to sorafenib, which is a multiple kinase inhibitor and the only clinically approved drug for the treatment of HCC. Unfortunately, the development of sorafenib resistance causes many difficulties. Therefore, a new chemotherapeutic agent is needed to treat HCC. Here, we show that TC Mps1 12 inhibits the proliferation of HCC cells by causing mitotic catastrophe. The data suggest that TC Mps1 12 could be an effective anticancer treatment for HCC. Cell viability assay Cells (7.5 × 10 3 cells per well) were placed in a 96-well plate and then treated with various concentrations of Mps1 inhibitors for indicated times. Cell viability was assessed by colorimetric MTT assay. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well, and the plate was incubated at 37°C for 4 h to allow formation of MTT formazan crystals. After the culture medium was removed, the formazan crystals were dissolved using DMSO. The absorbance was measured with a test wavelength of 570 nm and a reference wavelength of 650 nm (Choi et al., 2015) . Cell viability was also assessed by using the trypan blue exclusion test. 
Methods

Cell culture and drug treatment
Immunofluorescence staining
Cells were grown on coverslips and treated with the drugs indicated. The cells were fixed with 3% paraformaldehyde solution at room temperature for 10 min and then permeabilized with 0.5% Triton X-100 at room temperature for 5 min (Choi et al., 2015) . 
Western blotting
Cells were lysed using NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl pH 8.0, 0.5% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM sodium fluoride and 1 mM sodium orthovanadate) containing a protease inhibitor cocktail (Millipore, Darmstadt, Germany; 535140) on ice for 10 min. After centrifugation at 12 000× g for 5 min, the supernatant was saved as a crude cell extract. The crude cell extracts were boiled in the Laemmli buffer and then loaded onto a SDS-polyacrylamide gel. 
Time-lapse microscopy
The TSiN-H2B-RFP lentiviral construct was the kindly gift of Dr P.J. Galardy (Mayo Clinic). Lentivirus was prepared by transfection of HEK293T cells with TSiN-H2B-RFP lentiviral plasmid, psPAX2 packaging plasmid and pMD2.G envelope plasmid. HepG2 cells were infected with lentivirus encoding H2B-RFP in the presence of 8 μg·mL À1 polybrene. Time-lapse imaging was acquired using a Cell Observer (Carl Zeiss; Cell Observerâ Living Cells) equipped with a camera. Frames were recorded every 5 min. Cell morphology was visualized on a phase contrast microscope, and RFP was detected by fluorescence (Choi et al., 2015) .
Analysis of association of Mps1 expression with patient survival
The Mps1-coding TTK gene expressions of all 360 human liver hepatocellular carcinoma patients (up to 8 August 2016) were downloaded from The Cancer Genome Atlas (TCGA) (https:// tcga-data.nci.nih.gov). The data with more than 2000 days of survival day were excluded (21 cases). Overall, a total of 339 patients were analysed for overall survival (Zhang et al., 2015) . TTK transcript level was determined by Illumina HiSeq2000 RNA Sequencing Version 2 analysis and processed using the SUBIO platform (trial version). For each sample, TTK expression was defined as high (above median) or low (below median). The survival time of the patients was the date of death for deceased patients or the last contact date in alive patients for censoring. The association of transcript level with patient survival was visualized using Kaplan-Meier curves, and the significance of differences was assessed by a log-rank test using SPSS (version 23).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All experiments were repeated five times (n = 5); n refers to independent values, and not replicates. Each value is expressed as mean ± SEM. To control for unwanted sources of variation, we performed normalization to better compare the differences after the treatment and to reveal meaningful relevant trends. The viability of DMSO-treated control cells was considered to be 100%. The viability of the drug-treated cells was expressed as a % of the control. Protein expression levels were normalized to that of α-tubulin or GAPDH, and the expression levels of the drug-treated cells were expressed as fold changes over that of the DMSO-treated control cells, whose expression was set to 1. The SEM was normalized appropriately. The level of protein expression was expressed by a normalization procedure that generates control values with no variance (SEM = 0) to reduce the effect of any variations from different exposure of blotting, and these data were not subjected to parametric statistical analysis. Statistical analysis was performed using SPSS (version 23). Differences between two groups were evaluated by the Student's unpaired t-test for parametric analysis or Mann-Whitney test for nonparametric analysis. Differences between three or more groups were evaluated by one-way ANOVA (ANOVA) followed by a Tukey's honest significant difference (HSD) comparison for parametric analysis or Kruskal-Wallis test followed by Dunn's multiple comparison for non-parametric analysis. Post hoc tests were run only if F achieved P < 0.05, and there was no significant inhomogeneity. Statistical differences were considered significant from the control when P < 0.05 and are indicated by *, # or + .
Results
Mps1 is a potential therapeutic target for liver cancer
Mps1 is overexpressed in many cancers, suggesting that inhibiting Mps1 is a potential treatment for cancer. We downloaded the TTK mRNA levels from the TCGA dataset and performed Kaplan-Meier analysis. The information for the hepatocellular carcinoma patients is listed in Table 1 . Kaplan-Meier curves demonstrated that HCC patients with high TTK expression had significantly poorer overall survival (Figure 1) . Thus, Mps1 expression may be a strong predictive factor for survival of liver cancer patients.
TC Mps1 12 reduces the proliferation of HCC cells
Because a high expression of Mps1 is associated with low survival in liver cancer patients, the inhibition of Mps1 could represent one strategy for the treatment of cancer. We examined the effect of TC Mps1 12, a specific Mps1 inhibitor, on HCC cells. Exposure of both HepG2 and Hep3B cells to TC Mps1 12 at concentrations greater than 50 μM for 24 h caused a reduction in cell viability ( Figure 2A ). Although cell viability was not affected at concentrations below 10 μM TC Mps1 12 for 24 h, low concentrations (e.g. 0.1, 1 or 10 μM) inhibited Mps1 enzymatic activity as assessed by measuring the phosphorylation of Mps1 substrates. The levels of phosphorylated Mps1-T676 and BubR1-S670, both of which are phosphorylated by Mps1 in the presence of nocodazole, a microtubule depolymerizer, were reduced by TC Mps1 12 in a concentration-dependent manner ( Figure 2B ). To compare the effects of Mps1 inhibitors on cell viability, we treated cells for up to 72 h with Mps BAY2a, a specific Mps1 inhibitor, and SP600125, a broad-spectrum inhibitor of Table 1 Characteristics of HCC patients from TCGA
Low expression of Mps1
High expression of Mps1 Figure 1 Mps1-coding TTK expression is associated with low survival of HCC patients. An mRNA expression dataset was obtained from TCGA. Kaplan-Meier survival analysis was performed using data from 339 HCC patients. TTK expression was defined as high (above median) or low (below median). P-values were calculated using the log-rank test. serine/threonine kinases, including Mps1. The results show that the inhibitory effect was both dose and time dependent ( Figure 2C ). Treatment with Mps BAY2a resulted in the most significant reduction in cell viability. The inhibitory effects of TC Mps1 12 and SP600125 on cell viability were similar ( Figure 2C ). The inhibitory effect of SP600125 might be because it inhibits multiple kinases, resulting in the interruption of cell proliferation. Next, we examined the cytotoxic effects of TC Mps1 12 on three different cell types, namely, A549 lung cancer, HeLa cervical cancer and MDA-MB-231 breast cancer cells. Whereas TC Mps1 12 was most effective against MDA-MB-231 cells, it inhibited HCC cells and A549 and HeLa cells to a similar extent ( Figure 2D ). Assuming that HCC is relatively resistant to chemotherapy, TC Mps1 12 would be effective as an anti-HCC drug. The inhibitory effect of TC Mps1 12 on HCC cell proliferation was also confirmed by the dye exclusion test ( Figure 2E ). Interestingly, Hep3B cells were more sensitive than HepG2 cells to both high and low doses of TC Mps1 12 ( Figure 2A , C-E). Taken together, these data show that TC Mps1 12 retards the growth of HCC cells.
TC Mps1 12 causes the accumulation of chromosomal instabilities
Next, we examined the mechanism by which TC Mps1 12 retards cell proliferation. Mps1 regulates chromosome alignment and biorientation, and other Mps1 inhibitors disrupt chromosomal stability (Jelluma et al., 2008; Santaguida et al., 2010; Dou et al., 2015) . Therefore, we first examined the shape of the nuclei in TC Mps1 12-treated HepG2 and Hep3B cells by immunofluorescence staining ( Figure 3A ). We found that TC Mps1 12 treatment resulted in misaligned chromosomes, lagging chromosomes and micronuclei. The number of mitotic cells harbouring misaligned and lagging chromosomes was higher in TC Mps1 12-treated cells than in untreated cells ( Figure 3B ). In addition, TC Mps1 12 increased the number of micronucleicontaining cells in a time-dependent manner ( Figure 3C ). The effect of TC Mps1 12 on chromosomal stability was compared with those of other inhibitors including Mps BAY2a and SP600125. Mps BAY2a induced misaligned chromosomes, lagging chromosomes ( Figure 3B ) and micronuclei ( Figure 3C ). However, even though Mps BAY2a showed the most significant cytotoxicity ( Figure 2C ), Mps BAY2a had a weaker effect on micronuclei formation in Hep3B cells ( Figure 3C ) because the majority of Mps BAY2a-treated Hep3B cells underwent apoptosis, as determined by the formation of apoptotic bodies ( Figure 5E ). SP600125 treatment resulted in misaligned chromosomes and micronuclei ( Figure 3B , C), but not lagging chromosomes. TC Mps1 12 had a stronger effect on chromosomal instability than SP600125. This demonstrates that TC Mps1 12 induces chromosome missegregation, resulting in chromosomal instability.
TC Mps1 12 causes disorganization of centrosomes
The accumulation of chromosomal instabilities might be due to a defect in mitotic spindle and centrosome formation. To check whether Mps1 inhibition induces abnormalities in mitotic spindles and centrosomes, we visualized its effects by staining cells with antibodies specific for both α-tubulin and γ-tubulin. As shown in Figure 3A , TC Mps1 12-treated HepG2 and Hep3B cells contained misaligned chromosomes and multipolar spindles ( Figure 4A ). We also counted the number of centrosomes in interphase cells. While cells with one or two centrosome(s) are normal, cells with more than two centrosomes are abnormal. The number of multicentrosome-containing cells was increased significantly by TC Mps1 12 treatment in a time-dependent manner ( Figure 4B ). Mps BAY2a and SP600125 also increased the number of centrosomes ( Figure 4C, D) . This may cause a failure in chromosome segregation and, ultimately, aneuploidy.
TC Mps1 12 shortens the duration of mitosis and induces apoptosis
The disorganization of mitotic chromosomes may disrupt mitotic progression. Therefore, we first determined the proportion of mitotic cells undergoing prophase, prometaphase, metaphase, anaphase, telophase and cytokinesis ( Figure 5A ). TC Mps1 12-treated cells had a smaller proportion of mitotic cells than control cells, suggesting that cell proliferation was slow. Next, the effect of TC Mps1 12 on mitotic duration was examined by live cell imaging. The average time of mitotic progression in control HepG2 cells was 65 min; however, the time in TC Mps1 12-treated HepG2 cells was 25 min (Figure 5B, C) . This indicates that TC Mps1 12 treatment induces premature mitotic exit. In addition, whereas DMSO-treated cells divided normally into two daughter cells, some of TC Mps1 12-treated cells died ( Figure 5B ). Next, to identify the dead cells, we measured cleavage of PARP-1 as an indicator of apoptosis. TC Mps1 12-treated HepG2 and Hep3B cells showed significant cleavage of PARP-1 ( Figure 5D ). In addition, apoptosis was verified by measuring the apoptotic bodies after treatment with TC Mps1 12, Mps BAY2a or SP600125 ( Figure 5E ). Although SP600125 had a smaller effect on chromosome abnormality and micronuclei formation ( Figure 3B , C), SP600125 had a similar effect to TC Mps1 12 on apoptosis, probably because of inhibition of multiple kinases ( Figure 5E ). This suggests that the cytotoxic effect of SP600125 is not specifically related to Mps1 inhibition. As shown in Figure 2C , Mps BAY2a had the highest apoptotic effect in HCC cells ( Figure 5E ). In particular, the marked death of Mps BAY2a-treated Hep3B cells results in a smaller number of micronuclei-containing cells than expected ( Figure 3C ). Overall, this indicates that chromosomal instability and centrosome abnormality might lead to mitotic catastrophe.
TC Mps1 12 inactivates the SAC
We next investigated the mechanism by which TC Mps1 12 induces premature mitotic exit, even in the presence of misaligned chromosome and multipolar spindles. To activate SAC, we treated cells with nocodazole, a microtubule depolymerizer, which causes unattached microtubulekinetochores. We then examined the effect of TC Mps1 12 on the SAC ( Figure 6A ). Nocodazole treatment increased total levels of aurora B, PLK1, BubR1 and cyclin B1, demonstrating that the cell population was enriched with cells in mitosis. After treatment with TC Mps1 12, all levels were reduced, indicating that the inhibitor caused cells to exit nocodazole-induced mitosis. Nocodazole also induced phosphorylation of aurora B-T232, PLK1-T210 and BubR1-S670, which suggests activation of aurora B, aurora A and Mps1, respectively, and activates the SAC. The amount of phosphorylation significantly decreased in the presence of TC Mps1 12, indicating the inactivation of aurora B, aurora A and Mps1. Because phosphorylation of BubR1-S670 is sensitive to loss of microtubule attachment (Huang et al., 2008) , reduced phosphorylation in the presence of TC Mps1 12 implies that inhibiting Mps1 renders cells insensitive to unattached microtubules-kinetochores and they therefore fail to correct the errors. In addition, cyclin B1, one of the substrates for APC/C, was degraded in the presence of TC Mps1 12, indicating that SAC inactivation induces onset of the anaphase. Next, we examined the recruitment of SACrelated proteins to the kinetochore by immunofluorescence staining ( Figure 6B , C). We found that aurora B, BubR1, Mad2 and CENP-E were recruited to the kinetochore of prometaphase chromosomes in control cells and nocodazole-treated cells. By contrast, BubR1, Mad2 and The number of mitotic cells harbouring abnormal chromosomes was counted after treatment with 1 μM of TC Mps1 12, Mps BAY2a or SP600125 for 24 h. *P < 0.05 by one-way ANOVA followed by Tukey's HSD test, significantly different from corresponding DMSO-treated cells. (C) The number of interphase cells containing micronuclei after treatment with 1 μM of TC Mps1 12, Mps BAY2a or SP600125 for the indicated times was counted. Con (control) cells were treated with vehicle (DMSO) for 72 h. *P < 0.05, # P < 0.05 and + P < 0.05 by one-way ANOVA followed by Tukey's HSD test, significantly different from corresponding control cells. Each value is expressed as mean ± SEM (n = 5).
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CENP-E, all of which are substrates for Mps1, were not recruited (or the recruitment was much lower) to the kinetochore of prometaphase chromosomes in TC Mps1 12-treated cells or cells treated with nocodazole plus TC Mps1 12; however, localization of aurora B was unaffected. Although Mps1 activates aurora B (Jelluma et al., 2008; van der Waal et al., 2012) , it also acts downstream of aurora B Saurin et al., 2011) . In addition, live cell imaging revealed that nocodazole-treated cells were held at mitosis, while few cells underwent mitotic exit and cell death ( Figure 6D ). By contrast, the majority of TC Mps1 12-treated cells exited nocodazole-induced arrest ( Figure 6D ). Overall, these data demonstrate that TC Mps1 12 reverses nocodazole-induced SAC, resulting in mitotic slippage and a failure to correct microtubule-kinetochore unattachment.
Discussion
Mps1, which plays an essential role in mitotic progression, is emerging as a potential target for cancer treatment. Here, we showed that the Mps1 inhibitor TC Mps1 12 induced the formation of multicentrosomes as well as misaligned Several studies show that depletion of Mps1 affects mitosis. A lack of Mps1 perturbs centrosome duplication (Fisk et al., 2003) (Continued) BJP M Choi et al. Santaguida et al., 2010; Dou et al., 2015) , a failure to correct erroneous microtubule attachment (Jelluma et al., 2008) , cytokinesis failure (Fisk et al., 2003) and apoptosis (Jemaa et al., 2016) , shortens mitosis (Dou et al., 2015; Jemaa et al., 2016) , and prevents the recruitment of SAC-related proteins, including Mad1, Mad2, Bub1, BubR1 and RodZw10-Zwilch (Martin-Lluesma et al., 2002; Santaguida et al., 2010; Jemaa et al., 2016) . In addition, depletion of (Hewitt et al., 2010) Chromosome misalignment (Dou et al., 2015) Failure in recruitment of Mad1, Mad2, Bub1 and CENP-E (Hewitt et al., 2010) Short mitotic duration (Hewitt et al., 2010; Gurden et al., 2015) Apoptosis (Jemaa et al., 2016) BAY 1161909 0.34 nM (Wengner et al., 2016) Breast, lung and ovarian cancer (Wengner et al., 2016) Phase I ClinicalTrials.gov ID: NCT02138812 BAY 1217389 0.63 nM (Wengner et al., 2016) Phase I ClinicalTrials.gov ID: NCT02366949 CFI-402257 1.7 nM (Liu et al., 2016) MPI-0479605 1.8 nM (Tardif et al., 2011) Chromosome missegregation Colon cancer (Tardif et al., 2011 ) Hyperploidy Apoptosis Up-regulation of p53, p21 and γ-H2AX (Tardif et al., 2011) continues Effect of Mps1 inhibitor on hepatocellular carcinoma cells BJP Mps1 inhibits proliferation of HCC cells (Liang et al., 2014; Liu et al., 2015; Miao et al., 2016) . Overall, because the dysregulation of Mps1 leads to an accumulation of chromosomal instabilities and, finally, cell death, it may be a target for cancer therapeutics. Therefore, some Mps1 inhibitors have been developed and characterized. The enzymatic inhibition of Mps1 kinase by pharmacological inhibitors leads to similar phenotypes in Mps1-depleted cells, as summarized in Table 2 . TC Mps1 12 also induces chromosome misalignment and missegregation and the (Jemaa et al., 2013) formation of multicentrosomes, prevents the recruitment of SAC-related proteins and SAC activation, shortens mitotic duration and induces apoptosis. The difference between the other Mps1 inhibitors and TC Mps1 12 are their respective effects on polyploidy and centrosome number. For example, reversine (Jemaa et al., 2012a) , Mps BAY1, Mps BAY2a (Jemaa et al., 2013) and MPI-0479605 (Tardif et al., 2011) cause consecutive series of aborted mitosis and subsequently increase hyperploidy, including the formation of 8 N and 16 N DNA. However, we did not observe significant polyploidy in TC Mps1 12-treated cells using flow cytometry (data not shown). This may be due to the slow doubling time of HepG2 and Hep3B cells: 48 and 25 h respectively (Sagmeister et al., 2008) . If we had exposed the cells to TC Mps1 12 for more than 72 h, we may have detected hyperploidy. Also, the effect on centrosome number is dependent on the type of Mps1 inhibitor. TC Mps1 12 induces the formation of multipolar spindles and increases centrosome number ( Figure 4B ), and Mps BAY1 and Mps BAY2a also enhance centrosome number (Jemaa et al., 2013) . In contrast, although Mps1-IN-1 itself does not affect centrosome duplication, it does induce multipolar centrosomes, but only in cells with an overexpression of PLK4 (Kwiatkowski et al., 2010) . Overall, these differences might be dependent on the specificity of the Mps1 inhibitors.
We demonstrated that TC Mps1 12 has an inhibitory effect on the growth of HepG2 and Hep3B cells in vitro. Growth inhibition was more pronounced in Hep3B (p53-null) cells than in HepG2 (p53-wild type) cells. The dependency of Mps1 inhibitors on p53 is supported by previous findings using colon cancer cells. For example, SP600125 induces hyperploidy and apoptosis in p53-deficient HCT116 colon cancer cells (Jemaa et al., 2012b) and inhibits the growth of p53-deficient HCT116 xenografts, but not that of p53-proficient xenografts (Jemaa et al., 2012b) . Reversine aggravates hyperpolyploidy and apoptosis more in p53-deficient HCT116 cells than in p53-proficient HCT116 cells (Jemaa et al., 2012a) . MPI-0479605 had a more marked effect on apoptosis in p53-deficient Colo-205 colon cancer cells than in p53-proficient HCT116 cells (Tardif et al., 2011) . In fact, Mps1-mediated phosphorylation of p53 at Thr 18 stabilizes p53 and mediates the post-mitotic checkpoint. The failure of p53 phosphorylation in Mps1-siRNA-transfected cells induces polyploidy (Huang et al., 2009) . However, the apoptotic effects of Mps BAY1 and Mps BAY2a are greater in p53-proficient HCT116 cells than in p53-null HCT116 cells (Jemaa et al., 2013) . The relevance of p53 to Mps1 inhibitorinduced cell death needs to be examined in the context of each drug and cell type.
The anti-cancer effects of Mps1 inhibitor are improved by combining it with a microtubule poison (anti-mitotic drug). A reduction in Mps1 protein levels sensitizes cancer cells to vincristine or taxol (Janssen et al., 2009; Tannous et al., 2013) . In addition, chemical inhibition of Mps1 activity using SP600125 (Gyorffy et al., 2014) , BAY 1217389, BAY 1161909 (Wengner et al., 2016 ), Mps1-IN-3 (Tannous et al., 2013 , Mps BAY1 or Mps BAY2a (Jemaa et al., 2013) showed synergistic effects in terms of cell death and growth inhibition when tested in tumour xenografts in combination with vincristine or paclitaxel. Overall, the data presented herein suggest that the use of pharmacological inhibitors to prevent the mitotic function of Mps1 may be an effective anti-cancer approach.
